Objective: Depression is often not optimally treated during pregnancy, partially because of conflicting data regarding antidepressant medication risk. This meta-analysis was conducted to determine whether antenatal antidepressant exposure is associated with congenital malformations and to assess the effect of known methodological limitations. Data Sources: EMBASE, CINAHL, PsycINFO, and MEDLINE were searched from their start dates to June 2010. Keywords of various combinations were used, including, but not limited to depressive/mood disorder, pregnancy, antidepressant drug/agent, congenital malformation, and cardiac malformation. Study Selection: English language studies reporting congenital malformations associated with antidepressants were included. Of 3,074 abstracts reviewed, 735 studies were retrieved and 27 studies were included. Data Extraction: Two reviewers working independently assessed article quality. Data on use of any antidepressant, including fluoxetine and paroxetine specifically, were extracted. Outcomes included congenital malformations, major congenital malformations, cardiovascular defects, septal heart defects (ventral septal defects and atrial septal defects), and ventral septal defects only. Results: Nineteen studies were above quality threshold and make up the primary meta-analyses. Pooled relative risks (RRs) were derived by using random-effects methods. Antidepressant exposure was not associated with congenital malformations (RR = 0.93; 95% CI, 0.85-1.02; P = .113) or major malformations (RR = 1.07; 95% CI, 0.99-1.17; P = .095). However, increased risk for cardiovascular malformations (RR = 1.36; 95% CI, 1.08-1.71; P = .008) and septal heart defects (RR = 1.40; 95% CI, 1.10-1.77; P = .005) were found; the RR for ventral septal defects was similar to septal defects, although not significant (RR = 1.54; 95% CI, 0.71-3.33; P = .274). Pooled effects were significant for paroxetine and cardiovascular malformations (RR = 1.43; 95% CI, 1.08-1.88; P = .012). These results are contrasted with those addressing methodological limitations but are typically consistent. Conclusions: Overall, antidepressants do not appear to be associated with an increased risk of congenital malformations, but statistical significance was found for cardiovascular malformations. Results were robust in several sensitivity analyses. Given that the RRs are marginal, they may be the result of uncontrolled confounders. Although the RRs were statistically significant, none reached clinically significant levels.
T he consequences of a major depressive episode during pregnancy include effects on the mother, her infant, and family. [1] [2] [3] Although treatment is essential, the use of antidepressant medication during pregnancy has been found to be lower than other times of the life cycle. 4 One of the contributing factors for poor uptake of pharmacologic interventions appears to be concerns regarding the safety of antidepressant exposure for the fetus. 5 For example, preliminary reports of neonatal cardiovascular malformations following paroxetine exposure in early pregnancy 6 led to both the US Food and Drug Administration 6a and Health Canada 6b issuing advisories in 2005 warning about potential risks associated with the use of antidepressants during pregnancy. However, the warnings suggested a direct conflict between safety of the fetus and a mother's need for antidepressant medication, perhaps without regard to the documented negative effects of untreated depression on pregnancy outcomes. 3, 7 The results of prior meta-analyses have been conflicting. Several have found no evidence of increased risk of major congenital malformations above the baseline [8] [9] [10] rate, which has been widely cited as 1%-3% for any pregnancy in North America [11] [12] [13] [14] and less than 4% for minor congenital malformations. 15 The most recent meta-analyses did report an increased risk for congenital malformations 16 and cardiac malformations 13, 16 with paroxetine exposure specifically. Unfortunately, many individual studies have serious methodological limitations 17 that were not taken into account in the previous meta-analyses. For example, raw data unadjusted for confounders were used or studies were based on convenience samples. Furthermore, it is important to note the distinction between statistical significance and clinical significance when interpreting scientific evidence for clinical practice implications. The aim of this study was to synthesize the available data on congenital malformations, including cardiac, in infants of mothers who took antidepressant medications during pregnancy. In order to address the methodological limitations of the available research, we excluded studies below a quality threshold, used adjusted data where possible, examined for the effect of exposure contamination with any antidepressant use in the control group, and examined the influence of whether or not the samples were population based or obtained by convenience.
DATA SOURCES AND STUDY SELECTION
Following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines, 18 2 professional librarians with expertise in the areas of psychopharmacology and psychiatry independently conducted literature searches. A variety of keyword combinations were utilized, such as depressive/mood disorder; pregnancy/pregnancy trimesters; tricyclic antidepressant drugs; antidepressant drug/agent; selective serotonin reuptake inhibitors, SSRIs; monoamine oxidase inhibitors; prenatal or antenatal, infant/outcomes; congenital malformation, cardiac malformation (see supplementary material for full list of keywords). Strategies were based on the subject headings specific to the individual databases searched, combined with appropriate keywords and keyword phrases, and truncated if necessary. Concepts were combined with Boolean operators (AND, OR) to either broaden "like" concepts (OR) or narrow them (AND) to ensure more than 1 concept was included in the results. The explode feature (available for all of the databases searched, with the exception of MEDLINE In-Process and Scopus) was also used to broaden like concepts. The databases used included MEDLINE (Ovid), MEDLINE In-Process (Ovid) to access current literature (keyword searching only), PsycINFO (American Psychological Association; Ovid), CINAHL (Nursing and Allied Health), EMBASE (Excerpta Medica, Elsevier; Ovid), and Scopus (Elsevier) to access current literature (keyword searching only). The databases were searched from their start date to June 30, 2010 . Reference lists of reviews and meta-analyses were also searched for further articles, but none were found.
Inclusion and Exclusion Criteria
Cohort and case-control studies published in English were eligible for inclusion if they (1) reported original data and at least 1 malformation of interest, (2) reported on any pharmacologic antidepressant agent exposure (ie, selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors), (3) had a nonexposed comparison group of pregnant women for the antidepressant examined, and (4) provided sufficient data to calculate an effect size. Abstracts and conference proceedings were excluded, and unpublished data were not searched because the volume of potentially eligible studies would have made doing so infeasible. Outcomes of interest were identified by the research team as well as the advisory committee of key stakeholders for this program of research, which included representatives from psychiatry, family medicine, obstetrics, neonatology, public health, patient advocacy, and policy. The following outcomes were included in this meta-analysis: any congenital malformation, major congenital malformation (structural defects present at birth that have surgical, medical, or cosmetic significance or a significant effect on function or social acceptability 15, 19 ), cardiovascular malformation, septal cardiac defect (atrial septal defects or ventral septal defects), and ventral septal defects only as defined by the authors of the original publication. When more than 1 study had been published on the same cohort, we selected the study with the largest number of cases of malformations within each malformation outcome.
DATA EXTRACTION
The study was part of a larger research program developing a reference guide for physicians to assist in treatment discussions regarding antidepressant use during pregnancy with their patients. The data extraction and quality assessment processes for this program of research have been previously published. 7 Two independent research assistants completed the screening for all articles by their title and abstract, and eligible articles were retrieved. Data extraction forms were completed for all eligible studies and were based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 20 checklist. Data extracted included source, study design, participants (sample, control, demographics, and clinical characteristics), inclusion/exclusion criteria, antidepressants examined, dosage, duration of exposure, primary and secondary outcomes, outcome assessment methods, and loss to follow-up. Authors of original publications were sent requests for raw data if not provided in the article. Eight authors were contacted and 3 replied. Of these, 1 was unable to share data because of confidentiality issues, 1 was not able to meet our timeline, and the last 1 did not respond to our request for further clarification. low using a modification of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. 23 Studies were then categorized as "above quality threshold" (high, moderate, or low quality) or "below quality threshold" (very low quality). Results of the data extraction and quality assessment were compared between raters for each study, with any differences resolved through consensus by the principal investigators.
Statistical Analyses
Adjusted risk estimates were preferred when these were available, and odds ratios (ORs) and relative risks (RRs) were considered as equivalent measures of risk. We calculated ORs from the raw number of cases and controls when no such risk estimate was reported. For each outcome, we calculated 1 estimate of the OR for malformations for each article and pooled these risks across studies using randomeffects models. 24 We added 0.5 to cells with 0 cases when calculating the OR. 25 All analyses were conducted on the log scale. Visual inspection of funnel plots depicting the risk estimates (on the log scale) against their standard error and Egger regression-based test 26 were used to assess publication bias. Cochrane Q and I 2 were used to quantify between-study heterogeneity.
27,28 I 2 may be interpreted as the proportion of the total variance due to between-study heterogeneity. For studies reporting multiple exposure or control groups, these groups were combined in order to calculate a single risk estimate for each study where possible, if they were independent. For each outcome, our main analysis consisted of the pooled risk for the studies determined to be above quality threshold; further, we excluded studies that included some antidepressants in their control group (for example, when only selective serotonin reuptake inhibitor [SSRI] use was used as the exposure group but other antidepressants were not assessed and controls could have been, and in some cases were reported to have been, exposed to any antidepressants in their pregnancy) and also reran the analysis with articles that matched or adjusted their data in any way. Because of the generally low study quality, we also estimated the pooled risk excluding all convenience samples. We selected 2 specific antidepressants (fluoxetine and paroxetine) for a separate analysis of their effect on malformations where sufficient data were available, as more information was available for them compared to others. All analyses were conducted with Stata statistical software, version 10.1 (StataCorp LP) 29 and similar to our other work in Ross et al.
30

RESULTS
Of the 3,074 abstracts reviewed, 2,339 were excluded based on title and abstract. In total, 735 articles were retrieved and assessed for eligibility and 31 articles met the inclusion criteria ( Figure 1) . 31 Of these, 4 articles were excluded because they were duplicate analyses of studies already included in our quantitative analysis, leaving 27 studies for a quantitative analysis (Table 1) . Nineteen of the 27 studies were above the quality threshold, whereas 8 were below. Most studies reported data on more than 1 outcome (14 above quality threshold reported on any congenital malformation, 11 on any major malformation, 13 on any cardiovascular malformation, 9 on any septal cardiac defect [atrial septal defects or ventral septal defects], and 5 on ventral septal defects specifically). Eleven studies used a convenience sample, while 16 studies used either a a Other outcomes of interest in our research program. population-or hospital-based sample. Of all studies available, 13 clearly stated that no antidepressants were used in the control group and 21 reported adjusted data or applied matching. Information on fluoxetine was available from 0 to 7 studies depending on the outcome, and 0-8 studies were available for paroxetine.
Congenital Malformations
Overall, we pooled results from 12 studies* that were above quality threshold; the RR for congenital malformations was 0.93 (95% CI, 0.85-1.02; P = .113; Figure 2 ). Results were similar when studies were restricted to those studies that clearly excluded antidepressants from the control group. When studies with any adjustment were analyzed, all the studies regardless of quality, or 10 studies that did not use convenience samples (regardless of study quality), yielded similar results, with RRs ranging from 0.92 to 0.95 ( Table  2 ). The RRs from the meta-analyses with the individual antidepressants (fluoxetine and paroxetine) were similar in magnitude (ranging from 1.02 to 1.15) and not statistically significant (Supplementary eTable 1) .
Major Congenital Malformations
When only major malformations were analyzed, the pooled risk was small and not significant for the studies that were above quality threshold (RR = 1.07; 95% CI, 0.99-1.17; P = .095; Supplementary eFigure 1). Overall, the RRs for the other analyses were small, between 1.07 and 1.10 (Table  2) , but statistically significant depending on the subanalysis conducted. Results were not significant for any of the analyses for paroxetine use; however, the risk associated with the *Pedersen et al 54 and Reis and Källén 58 were excluded from this analysis, as these studies were population based and from the same country as Kornum et al 57 and Källén and Olausson, 45 respectively. 
Cardiovascular Malformations
With regard to cardiovascular malformations (13 studies above quality threshold) as the disease outcome, the pooled RR was small (RR = 1.36; 95% CI, 1.08-1.71; P = .008; Figure  3 ) but statistically significant in all analyses, ranging from 1.26 to 1.39 (see Table 2 ). One study 58 in particular had a strong influence on the results because of its sample size, detailed exposure measurement, and moderate study quality and was included in most subanalyses. Few studies were available for analyses stratified by medication. The risk associated with paroxetine was slightly higher (RR = 1.43; 95% CI, 1.08-1.88; P = .012; RRs between 1.43-1.47) and consistently statistically significant. The risk associated with fluoxetine was slightly lower and not statistically significant (RRs from 1.17 to 1.33; Supplementary eTable 1).
Septal Heart Defects (atrial septal defects or ventral septal defects)
Results involving the 9 studies above quality threshold indicated a significant association between exposure to antidepressants during pregnancy and an increased risk for any septal heart defect (atrial septal defects or ventral septal defects) (RR = 1.40; 95% CI, 1.10-1.77; P = .005; Supplementary eFigure 2). In subanalyses, the RRs were similar to the findings for any cardiovascular malformation (RRs between 1.17 and 1.40; Table 2 ) and statistically significant. Two studies 46, 58 had a particularly strong influence on the pooled estimate. There was no evidence suggesting that paroxetine or fluoxetine were associated with septal defects (Supplementary eTable 1) ; however, only 3 and 2 studies, respectively, were available for such an analysis. 
Ventral Septal Defects
Results for ventral septal defects were similar to any cardiac malformations (RR = 1.54; 95% CI, 0.71-3.33; P = .274; Supplementary eFigure 3), but they were not statistically significant; the few studies that investigated this outcome were generally small and reported very few or sometimes no case in either the exposure or the comparison group (Table 2 ). There were not enough studies to conduct a metaanalysis stratified by paroxetine or fluoxetine.
Publication Bias and Influential Studies
When the analyses were repeated with all identified studies regardless of study quality, we found very similar results. We did not find evidence for the presence of publication bias in any of our analyses (see Table 2 ). When we recalculated the pooled risk, excluding studies one by one, 1 study 58 was found to have had a particular influence on the derived pooled risk. This finding was most apparent for cardiac outcomes, for which exclusion of this study resulted in a slightly higher risk. For all other analyses, the estimate was well within the pooled CIs.
DISCUSSION
We conducted a systematic review and meta-analysis of the literature, examining associations between the use of any antidepressant and rates of overall congenital malformations, overall major congenital malformations, and, more specifically, cardiac malformations (as defined by the authors of the individual articles; see Table 1 ). Furthermore, on the basis of the available data for cardiac outcomes, we were then able to examine possible associations with antidepressant exposure and septal defects, as well as ventral septal defects alone. In addition to any antidepressant, we were also able to conduct analyses on 2 individual antidepressant medications (paroxetine and fluoxetine). These 2 medications were chosen on the basis of available evidence for meta-analyses on the outcomes of interest; the evidence reflects the focus of previously published literature. We found no evidence that antidepressants were associated with congenital malformations or major malformations in our primary analyses. Results were generally confirmed in several subanalyses, although there was an indication that antidepressants in general and, more specifically, fluoxetine exposure was associated with major congenital malformations. It is important to consider that these classifications of congenital and major malformations include many different malformations with different timelines of development, which can potentially confound relationships with a specific malformation, if one exists. 54 It is also important to note that we were able to analyze only 2 specific antidepressants, and so we cannot draw conclusions regarding the safety of other individual antidepressant drugs that we did not examine separately. Any antidepressant exposure was found to be associated with cardiac malformations in general. More specifically, when we looked at septal heart defects, we also found any antidepressant exposure to be associated. However, it is important to consider that statistical significance is not equivalent to clinical significance. There were only a few studies with which to further examine categorizations of cardiac malformations, and these studies had a small number of cases. We were able to analyze only ventral septal defects as a subcategory of septal defects, and these analyses were not significant, although the RRs were similar. Further research of high methodological quality is needed to confirm the results presented here.
There may be different associations between specific antidepressants and malformations. For example, antidepressants as a whole were associated with risk for any cardiac malformation, as was paroxetine, yet fluoxetine was not. Regardless of whether a class or individual effect exists, it is important to note that, overall, these results are largely reassuring, as even the nonsignificant meta-analyses did not return an RR higher than 1.67, with the highest significant one being 1.47, which is below the 2-fold increase benchmark that has been cited for clinical significance in this field. 52 The findings also are relieving, as depression during pregnancy is common, with rates as high as 20% being reported, 59 and 1.8%-2.1% of pregnancies having reported exposure to an SSRI, 60, 61 among the most frequently used of the antidepressants in pregnancy. 62 As far as we are aware, our study is the first meta-analysis to report a small increase in major malformations with fluoxetine, the oldest of the SSRIs in use. Note, however, that this was not a consistent finding, as our main analysis, which was with the higher quality studies, was not significant, although it was reduced to 4 studies. Several meta-analyses previously did report an increased risk for cardiovascular malformations with paroxetine (ie, Bar-Oz et al, 13 Wurst et al 16 ) but, unlike Wurst et al, 16 we did not find an increased risk for congenital malformations with this drug. Ours is the first meta-analysis, to our knowledge, to specifically examine the type of malformation implicated, and our results suggest that septal heart defects are associated with antidepressant exposure. However, although paroxetine was associated with cardiovascular malformations in general, it was not associated with septal heart defects in our analysis. Isolated ventricular malformations are a common type of congenital cardiovascular malformation, with an incidence rate of approximately 2%-5%. 63 These are typically small muscular defects, though they can be large or complex, and are often asymptomatic and/or close spontaneously early on and thus are frequently not detected. 63 Atrial septal defects, on the other hand, are less common 63 and are approximately 7% of congenital cardiac lesions. 64 As there are more severe and less severe types, some will require surgical intervention in infancy to avoid negative outcomes, 65 while others close spontaneously. 63 In contrast to the majority of ventricular septal defects that do close by the first year, it is often the atrial septal defects that are not diagnosed early and present in adulthood. 63 Previous research suggested that the inclusion of common reversible Grigoriadis et al heart defects such as the ventral ones may inflate any existing association found with antidepressant exposure. 13, 49, 52, 63 We attempted to differentiate between atrial septal defects and ventral septal defects, but there were not enough studies. Although our ventral septal defects analysis was not significant, the RRs were in a similar range to the overall septal defects analysis, which was significant. Note that the CIs were wide for the ventral septal defects-only analyses, and, thus, perhaps the results are biased. Sources of uncontrolled bias leading to the marginal increased risk for septal defects may include detection bias. 13 Women with depression may be more likely to have an ultrasound and echocardiogram in pregnancy and after birth. They may also have an increased use of health care services due to the depression itself or due to the publicity surrounding the risks of congenital malformations with SSRIs. Furthermore, many more women with depression may request diagnostic testing of their infants compared to healthy mothers. 13 All of the aforementioned potential sources of bias could increase the chance of false detection of an increased risk for septal defects and SSRI exposure. More research is certainly needed that focuses on these types of malformations, with the goal of determining whether an association with the type of cardiovascular effect exists, if it is dependent on a particular drug, or if indeed it is a class effect.
Strengths and Limitations
Perinatal researchers and clinicians have poor evidencebased information on effective treatments for perinatal women, as conducting the evidence-based gold standard, the randomized controlled trial, especially with pharmacological interventions, has ethical barriers among others. 66 Our reliance on observational studies and registries 67, 68 may propagate biases, as they have methodological limitations; thus, we keenly await new studies for replication and to confirm previous results. One of the strengths of our analysis was our attention to study quality. We limited our analyses to studies determined to be above a certain threshold of quality, according to the SAQOR, excluding studies below that threshold. Further, we ran subanalyses to examine whether limiting the data to those studies that (1) confirmed no antidepressant use in the control group, (2) had any adjustments made to the data, or (3) did not use convenience sampling among all the studies influenced any of the study results. We found few differences associated with study quality, suggesting that the findings presented in our analysis are quite robust. One exception was our analysis for major congenital malformations. While the pooled risk measure was not statistically significant in our main analysis using only studies above our quality threshold, the pooled estimates became statistically significant in 2 subanalyses. Regardless of the statistical significance, however, it is important to note that the RRs increased from 1.07 to only 1.10. As such, a very small and only marginally significant effect was present, even in these secondary analyses. Thus, largely, differences were small when examining all available data versus studies above our quality threshold. This is noteworthy given the known methodological flaws in these data as well as our concerns with our inability to make definitive conclusions based on previous research.
A further strength of our work rests on the fact that we used adjusted or matched data where possible in our metaanalyses, as well as running subanalyses for studies with any adjustments. Research in the area has been criticized for not taking into account "non-iatrogenic confounders" in pregnancy. 17 Indeed, many studies either did not adjust for any confounders, including depression, or applied matching in very small samples, which makes it difficult to assess whether such matching was successful. However, the most influential studies were also the large ones, and thus heavily influenced the results; these studies did adjust for several potential confounders. 45, 46, 50, 57, 58 Thus, most of our pooled risk estimates were heavily influenced by studies that did use adjusted data, including our subanalyses. Although this is relieving to a certain extent, these studies used data from population-based registries; they provide better evidence than that provided by data derived from convenience samples, but they are not randomized controlled trials, which provide the best evidence. The absence of evidence from randomized controlled trials highlights the importance for more research. There seems to be a clear need for more studies of high methodological quality that clearly separate antidepressant exposure across intervention and control groups and accurately adjust for the potential confounding effect of other risk factors for malformations.
Our study was limited by the quality of the articles available to be synthesized in our meta-analyses. Often, the specific outcomes examined were not precisely operationalized by authors of the original studies. For example, many studies reported to be examining "malformations, " but did not always specify whether they were major or minor. Studies often did not control for or assess if other psychotropic medications, in addition to antidepressants (ie, hypnotics), were used, the dose, or the timing of use during the pregnancy. We have noted that 1 of the most influential studies was Reis and Källén, 58 and, although it was above our quality threshold, it did not control for hypnotics or benzodiazepines. The size and study quality of the articles from the Swedish registries dominated the pooled effects, yet we did not actually have any knowledge of how many women took the medication as prescribed. A recent study by Källén et al 69 found that prescription data do not always accurately reflect use. Moreover, in another review 70 of how exposure to medication is classified in research utilizing administrative data, the authors concluded that there is tremendous uncertainty about the exposure. As fundamental factors, such as the dose of medication, timing of use during the perinatal period, duration of time the medication was taken, and the way in which women who discontinue using the medication at any point in pregnancy are dealt with in studies that use administrative data, the risk estimates may not be accurate. 70 Few studies included any information on diagnosis; that is, whether the medication was actually prescribed for depression. Antidepressants are also indicated for anxiety disorders, which are increasingly recognized as common in pregnancy 13, 71 ; these disorders themselves are also associated with adverse birth outcomes, including lower birth weight, 72 placental abruption, 73 and decreased fetal activity. 74 Finally, we were not able to control for the effects of depression itself, and it is possible that the disease itself may be associated with malformations, perhaps via its association with inadequate prenatal care. 59 Malnourishment overall (poor diet quality) and vitamin deficiencies (such as folic acid) are associated with various congenital malformations, including neural tube defects, congenital heart defects, and orofacial clefts. 75, 76 Depressed women are also more likely to smoke, 77 and not all studies controlled for smoking despite the known association of smoking with untoward effects. 78 Although our analysis was limited to what we deemed to be above quality threshold, and metaanalysis pools data so that conclusions can be reached with higher sample sizes, the original study limitations cannot be entirely ignored. 67 The data on the effects of in utero antidepressant exposure have grown recently, and it is now time to pay closer attention to study design in our interpretation of these findings. 17, 69, 70 It will be possible for future research to operationalize the precise malformations to be investigated and not group all. Expanding upon proposed future designs, 17 the ideal study, aside from a sufficiently powered multisite randomized controlled trial, would examine the effects within 1 diagnostic group (ie, unipolar major depression of moderate to severe symptomatology), excluding or controlling for known confounders (ie, other medications, smoking or alcohol use), with similar timed exposure (ie, within the first month of the first trimester) and compared to (a) euthymic women without a history of depression and any current medication use and to (b) depressed women of similar severity who are not treated with antidepressant medication. Such a study would indeed be challenging to conduct, as the ethics of randomization into the treatment versus no medication treatment arm can be debated as well as the potential effects of nonmedication treatment on outcome; however, it would be able to provide many answers.
Implications
The decision to use antidepressants during pregnancy must take into account the severity of the illness, whether there is a risk for suicide in particular, and the likelihood of relapse if medication is discontinued.
2 This is especially important to consider in light of a small baseline risk for malformations in the general population, with a small increase in risk potentially associated with antidepressant exposure for some outcomes where the absolute risk remains low. Moreover, it still remains to be determined whether some antidepressants are safer to use than others, as we were able to examine only 2 individual antidepressants in our meta-analyses (paroxetine and fluoxetine), or whether a class effect does indeed exist. We did not find a risk for cardiac malformations with the use of fluoxetine, for example, but we did find an increased risk with the use of paroxetine. Note, however, that although it was significant, the RR was still below 1.5 in all subanalyses conducted. While we were able to examine only the drugs for which the most data were available, future studies should specifically examine sertraline and citalopram, as data are also accumulating for these commonly used drugs. Potential risks of antidepressant treatment must be considered in light of other evidence. As many as 68% of women recruited from psychiatric settings who discontinued antidepressant use during pregnancy have been found to relapse, 62 leaving both the woman and her infant vulnerable to the potential effects of untreated perinatal depression. Data derived from obstetric clinics did not demonstrate a clear link between risk of a depressive episode and the discontinuation of antidepressant medication during pregnancy. 79 However, the study did demonstrate that women with more severe illness (greater than 4 depressive episodes prior to pregnancy) are at high risk for recurrence, even after accounting for the use of antidepressant medication. Treatment decisions must weigh the effects of untreated maternal depression (both in the immediate and long term) for a mother and fetus against the potential adverse effects of antidepressant exposure on the fetus. Moreover, untreated depression can have tremendous impacts on quality of life and experience of pregnancy; these factors must also be taken into account when making treatment decisions.
SUMMARY OF RESULTS AND IMPORTANT CONSIDERATIONS
Results
Any antidepressant medication exposure
Significantly associated with: Cardiovascular malformations (RR = 1.36) • Septal heart defects (atrial septal defects and ventral 
Considerations
Congenital malformations and major malformations (1) categories include a variety of malformations with different gestational timelines of development. The grouping of all malformations together may cause confounding of potential associations if they exist. Results seem robust, but uncontrolled confounders (2) cannot be excluded. For example, we cannot be sure the medication exposure from data derived from administrative sources accurately reflects use.
Because of limited data, we were able to examine only (3) septal defects (atrial septal defects and ventral septal defects) and then ventral septal defects, but not atrial septal defects alone. Although the ventral septal defects analysis was not • significant, the RRs were similar to the RRs found in the septal defects analysis, which was significant, suggesting that a significant association may indeed exist for ventral septal defects, which may be evident with more research. Alternatively, including common reversible heart • defects, such as ventral septal defects, could increase the chance of finding an association. There may be detection bias leading to a false detec-• tion of an association for antidepressant drugs and septal defects. On the basis of available data, we were able to analyze (4) only 2 individual medications (paroxetine and fluoxetine), and so it was not possible to determine if there was a class effect or an individual drug effect or to determine the safety of other individual antidepressant drugs. This bias in the available data on individual anti-• depressant medications also reflects previous research interests and foci. Few studies included any information on diagnosis. (5) The effects of a major depressive episode must also be considered. Supplementary eFigure 2. Exposure to any antidepressant and the risk of septal heart defect: meta-analysis results for studies above the quality threshold.
Abbreviations: see Figure 2 . Supplementary eFigure 3. Exposure to any antidepressant and the risk of ventricular septal defect (VSD): meta-analysis results for studies above the quality threshold. Abbreviations: see Figure 2 .
